Evidence map›Paper›PMID 24573252›Full record

ReviewInternational journal of molecular sciences2014

Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells.

Lucy H Swift, Roy M Golsteyn

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 203 citations in OpenAlex.

  1. ToxCompl completion of the DrugMatrix toxicogenomics database: an integrated resource for hypothesis generation.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  2. Article
  3. Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Polyploidy and Senescence of Cancer Cells: Impact of Cell Fusion.Advances in experimental medicine and biology · 2026
    Review
  9. Review
  10. Green Synthesis and Characterization of Silver Nanoparticles UsingInternational journal of molecular sciences · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Breast Cancer Exposomics.Life (Basel, Switzerland) · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lucy H SwiftCancer Cell Laboratory, Department of Biological Sciences, 4401 University Dr, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada. l.swift@uleth.ca.
Roy M GolsteynCancer Cell Laboratory, Department of Biological Sciences, 4401 University Dr, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada. roy.golsteyn@uleth.ca.
University of Lethbridge · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When a human cell detects damaged DNA, it initiates the DNA damage response (DDR) that permits it to repair the damage and avoid transmitting it to daughter cells. Despite this response, changes to the genome occur and some cells, such as proliferating cancer cells, are prone to genome instability. The cellular processes that lead to genomic changes after a genotoxic event are not well understood. Our research focuses on the relationship between genotoxic cancer drugs and checkpoint adaptation, which is the process of mitosis with damaged DNA. We examine the types of DNA damage induced by widely used cancer drugs and describe their effects upon proliferating cancer cells. There is evidence that cell death caused by genotoxic cancer drugs in some cases includes exiting a DNA damage cell cycle arrest and entry into mitosis. Furthermore, some cells are able to survive this process at a time when the genome is most susceptible to change or rearrangement. Checkpoint adaptation is poorly characterised in human cells; we predict that increasing our understanding of this pathway may help to understand genomic instability in cancer cells and provide insight into methods to improve the efficacy of current cancer therapies.

Indexed as

DNA DamageAdaptation, PhysiologicalAntineoplastic AgentsCell Cycle CheckpointsCell ProliferationDNA RepairGenomic InstabilityHumansMitosisNeoplasmsAntineoplastic Agents

Identifiers

PMID24573252
PMCPMC3975345
OpenAlexW2007100907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.